Neurocrine Biosciences Reports Second Quarter 2015 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Catalyst-Rich 6 Months Ahead for Neurocrine Bio. (NBIX), Cowen Notes
July 30, 2015 9:53 AM EDTCowen analyst Phil Nadeau reiterated an Outperform rating and boosted his price target on Neurocrine Bio. (NASDAQ: NBIX) to $55.00 (from $45.00), saying the company is gearing up for a catalyst-rich 6 months.
Nadeau commented, "NBIX's pipeline should yield a number of catalysts over the next 6... More
Neurocrine Biosciences (NBIX) Tops Q2 EPS by 1c
July 29, 2015 5:30 PM EDTNeurocrine Biosciences (NASDAQ: NBIX) reported Q2 EPS of ($0.28), $0.01 better than the analyst estimate of ($0.29).
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
... More